Stockreport

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloi...

Immix Biopharma, Inc.  (IMMX) 
PDF Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis Immix Biopharma, Inc. (Nasdaq:IMMX) All four patients treated with NX [Read more]